Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
Can China Catch the Falling Knife in Equity Markets?
28:42 - Bloomberg’s Stephen Engle reports on the current drop in Chinese equities and the government’s attempt to restore confidence in those markets. He speaks with Jonathan Ferro on Bloomberg Television’s “On The Move.” (Source: Bloomberg)
  • Greek 'Yes' Campaigners Have Momentum: Piccoli
  • The German Media’s Spin on the Greek Crisis
  • The Greek Bailout: Deal or no Deal?